NSE filing, NSE: SAKAR. Summary written from the filing by ALFA Finder's alert engine.
Sakar Healthcare Ltd: key numbers
- Share price
- ₹944.80
- Market cap
- ₹2,102 Cr
- Revenue (annual)
- ₹251.7 Cr
- Net profit (annual)
- ₹30.48 Cr
- P/E (TTM)
- 49.0×Sector 45.9×
- Promoter holding
- 51.70%-0.82% QoQ
- FII holding
- 12.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sakar Healthcare Ltd
All →Sakar Healthcare Earnings Call Transcript: Key Takeaways
Sakar Healthcare delivered exceptional growth as its oncology segment scales, with EBITDA doubling and margins expanding significantly due to product-mix shifts. Management is pivoting from a non-oncology focus to high-margin oncology formulations and APIs.
- Call
- Guides 35% growth
Sakar Healthcare Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue Rs87.4 Cr (+52% YoY), EBITDA Rs24.4 Cr (28% margin), PAT Rs11.3 Cr (+149%); pitch centres on oncology integration.
Sakar Healthcare Q2 FY27 Results: Net Profit ₹11.3 Cr, Up 151.1% YoY
Sakar Healthcare Ltd reported revenue from operations of ₹87.4 Cr (+51.7% YoY) and net profit of ₹11.3 Cr (+151.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹11.3 Cr · +151.1% YoY
Sakar Healthcare Board Meeting Date
Sakar Healthcare has scheduled a board meeting for October 23, 2026, to approve its unaudited quarterly financial results for the period ended September 2026.
Sakar Healthcare Business Update
Sakar Healthcare says its oncology export model is expanding, with 22 Marketing Authorizations granted and commercial supply starting from its EU GMP site. No monetary value stated.
Sakar Healthcare Other Announcement
Sakar Healthcare Limited appointed M/s. Kashyap R. Mehta & Partners as the company's Secretarial Auditors for a five-year term, effective September 22, 2026, following shareholder approval at the AGM.
Other results update announcements
All →Muthoot Finance Results Update
Muthoot Finance's consolidated profit after tax rose 39% year-on-year to ₹6,103 Crore for the half year. Consolidated loan AUM grew 42% to ₹2,09,317 Crore.
Aditya Birla Lifestyle Brands Results Update
ABLBL reported Q2 FY27 revenue up 11% to Rs.2266 Cr and PAT up 126% to Rs.53 Cr. Network expansion added over 100 stores during the quarter.
Advanced Enzyme Technologies Results Update
Advanced Enzyme Technologies issued a press release highlighting unaudited Q2 and half-year FY27 results. Revenue and profit grew year-on-year, with EBITDA and PAT margins reported.
Eveready Industries India Results Update
Eveready Industries reported Q2 and H1 FY27 unaudited results via press release, with consolidated Q2 revenue of Rs.428.2 crore, up 10.7%. The release also covers the Jammu alkaline facility's commercial production and new product launches.
Central Depository Services (India) Results Update
CDSL's Q2 FY27 media release reports consolidated total income up 22% and net profit up 24% year-on-year. It highlights results for the quarter and half year.
Akme Fintrade (India) Results Update
Akme Fintrade's press release shows H1 FY27 PAT up 19% and AUM crossing Rs. 1,000 crore. The unaudited results were approved by the board.